Antineoplastic effects of auranofin in human pancreatic adenocarcinoma preclinical models

BACKGROUND: Auranofin, a Food and Drug Administration–approved anti-rheumatic agent with anticancer properties for lung and ovarian cancer, has never been studied for pancreatic cancer. We hypothesize that auranofin may prevent pancreatic ductal adenocarcinoma progression by inhibition of Txnrd1 and...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Surg Open Sci
Autori principali: Rios Perez, Mayrim V., Roife, David, Dai, Bingbing, Pratt, Michael, Dobrowolski, Ryszard, Kang, Ya'an, Li, Xinqun, Augustine, Jithesh J., Zielinski, Rafal, Priebe, Waldemar, Fleming, Jason B.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Elsevier 2019
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8083010/
https://ncbi.nlm.nih.gov/pubmed/33981979
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.sopen.2019.05.004
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi